Watching the daily MACD like a hawk. A close above $15.75 sets us up for a break and cross run to $18+ IMO. Let's see
lol...would be nice to sell green one of these days,lol
Same, averaged in around $15.70.
Expecting to test $17.50s possibly by Friday.
Hoping for a quick turnaround over here....
Another 2.2M print. Huge loading the last 3 sessions
ARRY -Cant go into specifics but ARRY used to have the the largest parts of the Track systems ,The large quarter circle sheets that say ARRY used to be laser cut at a very high cost... Now they are being stamped out at a much more cost effective and faster pace!
Go time. 15.88s looking good!
Been there man good luck to you too
Just In: $ARRY Array Technologies, Inc (ARRY) Q3 2020 Earnings Call Transcript
Image source: The Motley Fool. Array Technologies, Inc (NASDAQ: ARRY) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Array Technologies, Inc (ARRY) Q3 2020 Earnings Call Transcript
Read the whole news ARRY - Array Technologies, Inc (ARRY) Q3 2020 Earnings Call Transcript
Just In: $ARRY Why Array Technologies Stock Jumped Today
Shares of Array Technologies (NASDAQ: ARRY) jumped higher today, up by 10% as of 3:10 p.m. EST, after the company reported third-quarter earnings. This was Array's first earnings release as a public company following its IPO last month. It does not yet have coverage from Wall St...
In case you are interested ARRY - Why Array Technologies Stock Jumped Today
That is within the realm of possibilities. Almost anticipated actually
Wow! ARRY would have to move up about $8.00 + for the remaining weeks of 2020..... This company has the framework, tools, components and rigging skills to partner with solar companies.
Shares of Array Technologies Inc. (ARRY) charged out of the gate, as the first trade was 34% above where the upsized initial public offering priced. A total of 47.5 million shares were sold in the IPO, as the New Mexico-based maker of ground-mounting systems used in solar energy projects sold 7 million shares to raise $154 million and a selling shareholder sold 40.5 million shares. The IPO priced at $22, above the top of the expected range of $19 to $21. With about 127.0 million shares outstanding, the IPO pricing valued the company at about $2.79 billion. The selling shareholder, a parent entity of the company controlled by Oaktree Capital, has increased the amount it planned to sell a number of times, starting at 26.75 million shares on Oct. 7, to 38.00 million shares on Oct. 13 and to 40.50 million shares late Wednesday. For the six months ended June 30, the company recorded net income of $76.1 million on revenue of $552.6 million, after a net loss of $5.2 million on revenue of $255.4 million in the same period a year ago. Goldman Sachs, J.P. Morgan, Guggenheim Securities and Morgan Stanley were the lead underwriters. The company went public at a time of good demand for IPOs, as the Renaissance IPO ETF (IPO) has rallied 28.7% over the past three months while the S&P 500 has gained 7.3%.
For more from MarketWatch: http://www.marketwatch.com/newsviewer
(END) Dow Jones Newswires
October 15, 2020 12:54 ET (16:54 GMT)
Array Technologies, Inc. is a manufacturer of ground-mounting systems used in solar energy projects. The Company’s principal product is an integrated system of steel supports, electric motors, gearboxes and electronic controllers. It sells its products to engineering, procurement and construction firms (EPCs) that build solar energy projects and to solar developers, independent power producers and utilities, often under master supply agreements or multi-year procurement contracts. The Company’s DuraTrack HZ v3 is single axis tracker and incorporates features, such as a single bolt per module mounting system. SmarTrack uses site-specific historical weather and energy production data, in combination with machine learning algorithms, to identify the position for a solar array in real time.
ARRAY used to have the duratrack sun tracker assembly laser cut at high cost per piece they are now being stamped in a stamping press at a rate of i believe 25/30 parts a minute at A FRACTION OF THE COST of them being lasercut -big cost saving..
THE ASK LOOKS THIN ENOUGH FOR OVER $100. BUT SOME PEOPLE NEVER SEE THE BIGGER PICTURE AND ARE ALWAYS QUICK TO TAKE $1000 TO $2000 PROFITS AND END UP CLOGGING THE ASK WITH THEIR GOODS.
Speculating this will be over $100 a share come January 2021
ARRY IPO TODAY. NOW ARRAY TECHNOLOGIES, NO LONGER ARRAY BIOPHARMA. GOOD THING IS NASDAQ IS UNLIKELY TO MANIPULATE PRICES ON IPO DEBUT DAY. IPO PRICED AT $22, OPENED AT $29. NOW AT $33.
News: $ARRY Array Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Array BioPharma Inc. is Fair to Shareholders - ARRY
NEW YORK, June 17, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Array BioPharma Inc. (“Array” or the “Company”) (NASDAQ: ARRY) to Pfizer Inc. (“Pfizer”) is fair to Array sharehold...
Read the whole news https://marketwirenews.com/news-releases/array-merger-investigation-halper-sadeh-llp-announces-investigation-into-whether-the-sale-of-array-biopharma-inc-is-fair-to-shareholders-arry-8369178.html
News: $ARRY Pfizer to Acquire Array BioPharma
— Proposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term — Opportunity to strengthen category leadership in Oncology with the addition of a breakthrough comb...
Find out more https://marketwirenews.com/news-releases/pfizer-to-acquire-array-biopharma-8367138.html
News: $ARRY Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer
BOULDER, Colo. , May 21, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI ® (encorafenib), a BRAF inhibitor, MEKTOVI ® (binimetinib), ...
Read the whole news https://marketwirenews.com/news-releases/array-biopharma-announces-braftovi-mektovi-cetuximab-meet-primary-endpoints-of-orr-and-os-in-phase-3-beacon-crc-trial-interim-analysis-for-the-treatment-of-braf-v600e-mutant-metastatic-colorectal-cancer-8221868.html